U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07425483) titled 'CAR-NK Cells (CL-NK-003) in Pancreatic Cancer' on Feb. 12.
Brief Summary: This is a single-center, open-label, first-in-human, fixed-dose study in patients with pancreatic cancer.
Study Start Date: Feb. 12
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Intervention:
BIOLOGICAL: CL-NK-003
Fixed-dose (3 x 10^9 cells)
Recruitment Status: RECRUITING
Sponsor: Changhai Hospital
Information provided by (Responsible Party): Zhuan Liao, Changhai Hospital
Published by HT Digital Content Services with permission from Health Daily Digest....